LLY · News · 20260901N

Reimbursement and Payer Mix

ELI LILLY & Co · 2026-09-01 · Importance 32 · Surprise 24

Employers and insurers are reducing coverage for GLP-1 medicines used for weight loss. The FDA expanded Mounjaro’s label to include cardiovascular risk reduction for patients with type 2 diabetes, supporting Lilly’s reimbursement arguments. The expanded indication may provide medical-necessity support for continued coverage, although it primarily applies to diabetes treatment rather than general obesity coverage.

Key facts